HMGB2
High mobility group protein B2
Also known as: HMG2, HMGB2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P26583
- Gene
- HMGB2
- Ensembl
- ENSG00000164104
- Chromosome
- 4
- Canonical length
- 209 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
- Subcellular location
- Nucleoplasm,Nucleoli,Principal piece,Annulus
- Secretome location
- Secreted to blood
OverviewNCBI Gene
This gene encodes a member of the non-histone chromosomal high mobility group protein family. The proteins of this family are chromatin-associated and ubiquitously distributed in the nucleus of higher eukaryotic cells. In vitro studies have demonstrated that this protein is able to efficiently bend DNA and form DNA circles. These studies suggest a role in facilitating cooperative interactions between cis-acting proteins by promoting DNA flexibility. This protein was also reported to be involved in the final ligation step in DNA end-joining processes of DNA double-strand breaks repair and V(D)J recombination. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
209 residues, UniProt reviewed canonical sequence.
>P26583|HMGB2
1 MGKGDPNKPR GKMSSYAFFV QTCREEHKKK HPDSSVNFAE FSKKCSERWK TMSAKEKSKF
61 EDMAKSDKAR YDREMKNYVP PKGDKKGKKK DPNAPKRPPS AFFLFCSEHR PKIKSEHPGL
121 SIGDTAKKLG EMWSEQSAKD KQPYEQKAAK LKEKYEKDIA AYRAKGKSEA GKKGPGRPTG
181 SKKKNEPEDE EEEEEEEDED EEEEDEDEELocalizationUniProt · AlphaFold · HPA
Whether an antibody against HMGB2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.48
- Highest tissue expression
- 2,215 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 2,215 nTPM
- thymus: 874 nTPM
- lymph node: 364 nTPM
- tonsil: 364 nTPM
- spleen: 156 nTPM
- appendix: 138 nTPM
Single-cell type
- monocyte progenitors: 1,546 nCPM
- neutrophils: 1,241 nCPM
- erythrocyte progenitors: 1,126 nCPM
- neutrophil progenitors: 1,076 nCPM
- extravillous trophoblasts: 1,000 nCPM
- migrating cytotrophoblasts: 700 nCPM
Immune cell
- basophil: 802 nTPM
- eosinophil: 408 nTPM
- neutrophil: 318 nTPM
- T-reg: 267 nTPM
- memory CD4 T-cell: 138 nTPM
- classical monocyte: 136 nTPM
Brain region
- white matter: 33 nTPM
- pons: 30 nTPM
- basal ganglia: 30 nTPM
- cerebral cortex: 30 nTPM
- hypothalamus: 30 nTPM
- medulla oblongata: 29 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about HMGB2.
Disease | ImmuneIEDB
Conditions an epitope on HMGB2 was assayed in.
- rheumatoid arthritis B cell
ReferencesPubMed · IEDB
Publications for HMGB2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
4 publications
- Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases.
1998 · J Rheumatol · RCR 1.6 · 61 citations - Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC).
1998 · Clin Exp Immunol · RCR 1.3 · 47 citations - High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis.
1999 · Gut · RCR 1.2 · 48 citations - Conformational difference in HMGB1 proteins of human neutrophils and lymphocytes revealed by epitope mapping of a monoclonal antibody.
2004 · J Biochem · RCR 0.2 · 9 citations
Reference: B cellIEDB
1 publication
- Disordered Antigens and Epitope Overlap Between Anti-Citrullinated Protein Antibodies and Rheumatoid Factor in Rheumatoid Arthritis.
2020 · Arthritis Rheumatol · RCR 1.7 · 30 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.32
- gnomAD pLI
- 0.95
- gnomAD missense Z
- 1.61
- DepMap mean gene effect
- 0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell chemotaxis
- cellular response to lipopolysaccharide
- chromatin organization
- chromatin remodeling
- defense response to Gram-negative bacterium
- defense response to Gram-positive bacterium
- DNA geometric change
- DNA topological change
- double-strand break repair via nonhomologous end joining
- extrinsic apoptotic signaling pathway via death domain receptors
- inflammatory response to antigenic stimulus
- innate immune response
- male gonad development
- negative regulation of DNA-templated transcription
- negative regulation of extrinsic apoptotic signaling pathway via death domain receptors
- negative regulation of gene expression
- negative regulation of transcription by RNA polymerase II
- nucleosome assembly
- positive regulation of DNA-templated transcription
- positive regulation of endothelial cell proliferation
- positive regulation of erythrocyte differentiation
- positive regulation of innate immune response
- positive regulation of interferon-beta production
- positive regulation of megakaryocyte differentiation
- positive regulation of transcription by RNA polymerase II
- regulation of neurogenesis
- regulation of stem cell proliferation
- regulation of transcription by RNA polymerase II
- response to lipopolysaccharide
- response to steroid hormone
- spermatid nucleus differentiation
- V(D)J recombination
Molecular functions
- chemoattractant activity
- cis-regulatory region sequence-specific DNA binding
- damaged DNA binding
- DNA binding
- DNA binding, bending
- DNA-binding transcription factor binding
- double-stranded DNA binding
- four-way junction DNA binding
- non-sequence-specific DNA binding, bending
- protein domain specific binding
- RAGE receptor binding
- RNA binding
- single-stranded DNA binding
- supercoiled DNA binding
- transcription cis-regulatory region binding
- transcription coactivator activity
- transcription factor binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of HMGB2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads HMGB2 as an antibody target. Whether an autoantibody or antibody against HMGB2 could matter depends on whether native HMGB2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
HMGB2 is annotated as secreted, so native HMGB2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label HMGB2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...